Last updated: 2026-10-14 00:10:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Spero Therapeutics, Inc. (SPRO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.16, with a market capitalization of $69.88M and a P/E ratio of 9.31. Over the past 52 weeks, its price has ranged from $1.08 to $3.08. This page covers its latest market performance, valuation, price trends and company information.
$69.88M | |
$1.19 | |
$23.64 | |
$0.51 | |
$1.18 | |
266.36K | |
1.04M | |
9.31 | |
$3.08 | |
$1.08 | |
-- | |
-- |
Spero Therapeutics, Inc. (SPRO) last closed at $1.18 as of 2026-10-13 23:31:00, unchanged from the previous close of $1.18.
During the latest regular trading session, SPRO traded between $0.51 and $23.64, with a volume of 266.36K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Spero Therapeutics, Inc. (SPRO) moved from $1.19 to $1.16, representing a decline of 2.94% ($0.03).
The stock traded between $1.13 and $1.27 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 572.44 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 3.7%
SPRO is currently trading at $1.16, placing it 3.7% of the way from its 52-week low of $1.08 to its 52-week high of $3.08. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 25 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Spero Therapeutics, Inc. (SPRO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.